Crewe Advisors LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) during the first quarter, according to its most recent filing with the SEC. The fund acquired 393 shares of the company’s stock, valued at approximately $50,000.
Other institutional investors have also added to or reduced their stakes in the company. First PREMIER Bank bought a new position in shares of Novo Nordisk A/S in the first quarter worth $25,000. CNB Bank bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $26,000. Dixon Mitchell Investment Counsel Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter worth approximately $26,000. Orion Capital Management LLC purchased a new stake in Novo Nordisk A/S in the first quarter valued at approximately $26,000. Finally, Frank Rimerman Advisors LLC bought a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Trading Down 0.3 %
Shares of NYSE:NVO traded down $0.35 during midday trading on Friday, hitting $127.51. 1,198,635 shares of the stock traded hands, compared to its average volume of 4,410,833. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $572.20 billion, a PE ratio of 43.70, a P/E/G ratio of 1.32 and a beta of 0.41. Novo Nordisk A/S has a one year low of $77.96 and a one year high of $148.15. The business’s 50 day moving average is $138.79 and its two-hundred day moving average is $128.11.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on NVO shares. The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Argus lifted their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, July 1st. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $145.67.
Check Out Our Latest Research Report on NVO
Novo Nordisk A/S Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Read More
- Five stocks we like better than Novo Nordisk A/S
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- About the Markup Calculator
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- The 3 Best Fintech Stocks to Buy Now
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.